

AMENDMENTS TO THE SPECIFICATION

Please delete the first full paragraph on page 6, and replace it with the following amended paragraph:

Also, other pyrimidine-5-carboxamide derivatives useful as PDE 5 inhibitors (e.g., Patent Reference 3; the 2-position substituent of the ~~piperidine~~pyrimidine ring is a lower alkylamino or indanylamino group which may be substituted), NOS inhibitors (e.g., Patent Reference 4; imidazolylphenyl group and 1,3-benzodioxol-5-yl group are essential), anticancer agents (e.g., Patent Reference 5; the 4-position substituent of the ~~piperidine~~pyrimidine ring is an amino group which is directly bonded to a ring group), anti-fungal agents (e.g., Patent Reference 6; an alkynyl group is essential on the 4-position substituent of the ~~piperidine~~pyrimidine ring) and the like have been reported, but all of them do not disclose or suggest on the inhibitory activity for STAT 6 activation.

Please delete the first full paragraph on page 73, and replace it with the following amended one:

A 10 ml 1,4-dioxane solution of 738 mg of tert-butyl 4-(4-{[5-(aminocarbonyl)-4-(benzylamino)pyrimidin-2-yl]amino}phenyl)~~piperidine~~piperazin-1-carboxylate was mixed with 2.77 ml of 4 M hydrogen chloride/1,4-dioxane solution and 3 ml of water, followed by stirring at 90°C for 2 hours. The reaction mixture was cooled down to room temperature, diluted with water, mixed with saturated sodium bicarbonate aqueous solution and then extracted with an ethyl acetate-THF mixed solution. After washing of the organic layer with saturated brine and subsequent evaporation of the solvent, the resulting solid was recrystallized (THF-ethanol) to

obtain 413 mg of 4-benzylamino-2-{{4-(piperazin-1-yl)phenyl}amino}pyrimidine-5-carboxamide as ivory-colored crystals.

Please delete the title of Example 263 on page 134, and replace it with the following amended one:

Example 263 Evaluation using SO₂ gas-induced intra-alveolar neutrophil infiltration model
~~mouse asthma model~~